The combination treatment increased the effector CD44+ CD8+ PD1− subset and decreased the proportion of terminally-differentiated CD103+ KLRG-1+ T-regulatory cells, as well as increased XCR-1 expression on conventional dendritic cells type-1 (cDC1) in the tumor, and tumor-drained lymph nodes (TDLNs). The gene discussed is CD44; the disease is neoplasm.